Nuo Therapeutics Inc. (NUOT) 0.2300 $NUOT
Nuo Therapeutics' (NUOT) CEO Martin Rosendale on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu May 14, 10:17AM CDT
Nuo Therapeutics Reports First Quarter 2015 Results and Provides Commercial Update
GlobeNewswire - Wed May 13, 4:50PM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT) a pioneer in biodynamic therapies, today reported financial results for the first quarter ended March 31, 2015 and provided an update on commercialization activities.
NUO Therapeutics to Hold First Quarter 2015 Conference Call on Thursday, May 14 at 8:00 a.m. Eastern Time
GlobeNewswire - Mon May 11, 7:30AM CDT
NUO Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, announced today that it will report financial results for the first quarter of 2015 on Wednesday, May 13, 2015, after the close of market.
Nuo Therapeutics Presents New Clinical Evidence Supporting Aurix at 2015 SAWC Spring Meeting
GlobeNewswire - Mon May 04, 8:03AM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced three patient case studies demonstrating the efficacious healing capabilities of Aurix(TM), a biodynamic hematogel, in treating chronic wounds were presented at the 28 Annual Symposium on Advanced Wound Care (SAWC) Spring Meeting, held in San Antonio, Texas from April 29 - May 3, 2015.
Nuo Therapeutics Announces Senior Management and Board Changes
GlobeNewswire - Thu Apr 30, 3:30PM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT) a pioneer in biodynamic therapies, today announced that David Jorden, current Executive Chairman of the Company's Board of Directors, has been appointed Acting Chief Financial Officer officially effective May 24, 2015 but will assume some roles immediately. Mr. Jorden, who was named Executive Chairman in 2012 and has served on the Company's Board since 2008, replaces Steven Shallcross, who has resigned effective May 25, 2015 to pursue another career opportunity. The Company plans to initiate an executive search for a permanent successor to Mr. Shallcross.
Nuo Hit By Perfect Storm In 2014, But We See Blue Sky Ahead
Jason Napodano, CFA - at Seeking Alpha - Thu Apr 02, 2:34PM CDT
Nuo Therapeutics Reports Full-Year 2014 Financial Results
GlobeNewswire - Tue Mar 31, 4:00PM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT) a pioneer in biodynamic therapies, today reported financial results for the year ended December 31, 2014.
Next Week In Biotech: AcelRx's New CEO, RXi And Celladon Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 27, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
IMDZ: 22.78 (+1.67), ARGS: 7.88 (+0.20), RXII: 0.50 (-0.01), CTSO: 6.24 (+0.31), ADK: 3.97 (-0.03), RGDX: 0.34 (+0.01), CLDN: 2.22 (+0.04)
NUO Therapeutics to Hold Fourth Quarter and Full Year 2014 Conference Call on Wednesday, April 1 at 8:00 a.m. Eastern Time
GlobeNewswire - Wed Mar 25, 7:45AM CDT
NUO Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, announced today that it will report financial results for the fourth quarter and full year 2014 on Tuesday, March 31, 2015, after the close of market.
Malignant Glioma Therapeutics Pipeline Review 2015 - 10 Companies & 18 Drug Profiles
M2 - Tue Mar 03, 5:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/5rhrvv/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Eli Lilly and Company - iDD biotech SAS - Lipopharma Therapeutics SL - Merck & Co., Inc. - Nuo Therapeutics, Inc. - Orbus Therapeutics, Inc. - Sanofi - Stemline Therapeutics, Inc. - ZIOPHARM Oncology, Inc. Drug Profiles - Ad-RTS-IL-12 - ALD-451 - Dendritic Cell Therapy for Malignant Gliomas - Dendritic Cell Therapy for Oncology - eflornithine hydrochloride - galunisertib - GliAtak - IDD-004 - LD-224 - marizomib - Minerval - Monoclonal Antibody Conjugated to Antagonize EGFR for Brain Tumor and Glioblastoma Multiforme - pembrolizumab - SL-701 - Small Molecule for Brain Cancer and Malignant Glioma - Vaccine to Target Survivin for Malignant Glioma - Vaccine to Target Wilm's Tumor 1 for Oncology - voxtalisib For more information visit http://www.researchandmarkets.com/research/5r...ant_glioma
ZIOP: 9.35 (+0.18), MRK: 60.01 (-0.22), LLY: 72.94 (+0.04), STML: 13.42 (-0.01)
Nuo Therapeutics Initiates Phase 4 Study of Aurix(TM) Under CMS Coverage With Evidence Development Program
GlobeNewswire - Thu Feb 19, 7:30AM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced the initiation of a new clinical study (Au Study) that is comprised of three randomized controlled protocols that examine the efficacy of Aurix(TM), a biodynamic hematogel, for use in diabetic foot ulcers, venous leg ulcers and pressure ulcers (bed sores).
Coronary Artery Disease Therapeutics Pipeline Market H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Feb 05, 7:31AM CST
The report "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease). Coronary artery disease (Ischemic Heart Disease) is the most common type of heart disease. Coronary artery disease is the tightening or blockage of the coronary arteries. A severe adequate blockage may cause a heart attack. Coronary artery disease (Ischemic Heart Disease) is the foremost cause of death in US, UK and globally. Most ischaemic heart disease is caused by atherosclerosis. However there are a number of risk factors.
CRME: 9.03 (+0.34), GILD: 111.00 (+1.70), PSTI: 2.72 (+0.04), MRK: 60.01 (-0.22), AZN: 68.74 (-0.55), EGRX: 61.94 (+1.02), BMY: 68.00 (+0.36), RGDO: 1.21 (unch)
Nuo Therapeutics and Rohto Pharmaceutical Co. Sign Exclusive Licensing and Distribution Agreement for Aurix in Japan
GlobeNewswire - Thu Jan 08, 3:06PM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT) a pioneer in biodynamic therapies, today announced that it has signed an exclusive licensing and distribution agreement for the Aurix System with Rohto Pharmaceutical Co., Ltd. ("Rohto"
, one of Japan's leading pharmaceutical, health and wellness companies. Under the terms of the agreement, Nuo will receive an upfront payment from Rohto in exchange for an exclusive license and the right to develop and commercialize Aurix in the Japanese market. The agreement also contemplates additional royalty payments based on the net sales of Aurix in Japan and an additional future cash payment in the event specific milestones are met. In turn, Nuo will pay a one-time fee to Millennia Holdings (Millennia) to terminate the September 2009 license and distribution agreement. Millennia has been instrumental in establishing the advanced wound care market in Japan, and will continue to work with Rohto to develop the market for Aurix. Further, Rohto has assumed all responsibility for securing the Marketing Authorization ("MA" from Japan's Ministry of Health, Labour and Welfare ("MHLW" , while Nuo will provide relevant product information, as well as clinical and other data to support Rohto's MA application.
15 Biotech Names For 2015
Jason Napodano, CFA - at Seeking Alpha - Mon Jan 05, 1:37PM CST
NBIX: 43.14 (+1.51), NVIV: 12.09 (-0.97), LPCN: 7.60 (-0.06), EPRS: 5.94 (+0.33), DEPO: 20.22 (-0.32), ASPX: 100.96 (unch), BCLI: 3.59 (-0.07), CUR: 1.71 (+0.01)
Critical Limb Ischemia - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/m55nsq/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aastrom Biosciences - AnGes MG - Apceth GmbH & Co - Athersys - Hemostemix - Human Stem Cells Institute - Juventas Therapeutics - Kasiak Research - Multi Gene Vascular Systems - NeoStem - Nuo Therapeutics - Pharmicell - Pluristem Therapeutics - ReNeuron Group - Stempeutics Research Private - TikoMed - ViroMed For more information visit http://www.researchandmarkets.com/research/m5...tical_limb
PSTI: 2.72 (+0.04)
Nuo Therapeutics Wins 2014 MarCom Platinum Award
GlobeNewswire - Tue Dec 02, 7:30AM CST
Nuo Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced that it, along with its marketing partner BLDG Health, was presented with the 2014 Platinum MarCom Award by the Association of Marketing and Communication Professionals (AMCP) for its sales education modules designed to support the recently launched Aurix System(TM). In addition, Nuo and BLDG Health were awarded with an Honorable Mention for the Aurix System(TM) microsite in the 2014 competition.
Nuo Therapeutics to Sponsor Pre-Event for 35th National Veterans Wheelchair Games
GlobeNewswire - Mon Nov 17, 7:42AM CST
Nuo Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced that it is sponsoring the 35 National Veterans Wheelchair Games Business & Community Leaders' Breakfast, co-presented by the Paralyzed Veterans of America (PVA) and the U.S. Department of Veterans Affairs (VA), taking place November 18, 2014 at Southern Methodist University in Dallas, Texas. This sponsorship marks the first in a series of initiatives reinforcing the Company's commitment to the PVA and the members it serves.
Nuo Therapeutics' (NUOT) CEO Marty Rosendale on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 1:34PM CST
Nuo Therapeutics' (NUOT) CEO Martin Rosendale on Q1 2015 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu May 14, 10:17AM CDT
Nuo Therapeutics Reports First Quarter 2015 Results and Provides Commercial Update
GlobeNewswire - Wed May 13, 4:50PM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT) a pioneer in biodynamic therapies, today reported financial results for the first quarter ended March 31, 2015 and provided an update on commercialization activities.
NUO Therapeutics to Hold First Quarter 2015 Conference Call on Thursday, May 14 at 8:00 a.m. Eastern Time
GlobeNewswire - Mon May 11, 7:30AM CDT
NUO Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, announced today that it will report financial results for the first quarter of 2015 on Wednesday, May 13, 2015, after the close of market.
Nuo Therapeutics Presents New Clinical Evidence Supporting Aurix at 2015 SAWC Spring Meeting
GlobeNewswire - Mon May 04, 8:03AM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced three patient case studies demonstrating the efficacious healing capabilities of Aurix(TM), a biodynamic hematogel, in treating chronic wounds were presented at the 28 Annual Symposium on Advanced Wound Care (SAWC) Spring Meeting, held in San Antonio, Texas from April 29 - May 3, 2015.
Nuo Therapeutics Announces Senior Management and Board Changes
GlobeNewswire - Thu Apr 30, 3:30PM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT) a pioneer in biodynamic therapies, today announced that David Jorden, current Executive Chairman of the Company's Board of Directors, has been appointed Acting Chief Financial Officer officially effective May 24, 2015 but will assume some roles immediately. Mr. Jorden, who was named Executive Chairman in 2012 and has served on the Company's Board since 2008, replaces Steven Shallcross, who has resigned effective May 25, 2015 to pursue another career opportunity. The Company plans to initiate an executive search for a permanent successor to Mr. Shallcross.
Nuo Hit By Perfect Storm In 2014, But We See Blue Sky Ahead
Jason Napodano, CFA - at Seeking Alpha - Thu Apr 02, 2:34PM CDT
Nuo Therapeutics Reports Full-Year 2014 Financial Results
GlobeNewswire - Tue Mar 31, 4:00PM CDT
Nuo Therapeutics, Inc. (OTCQX:NUOT) a pioneer in biodynamic therapies, today reported financial results for the year ended December 31, 2014.
Next Week In Biotech: AcelRx's New CEO, RXi And Celladon Earnings
SA Editor Mike Taylor - Seeking Alpha - Fri Mar 27, 8:00AM CDT
Every Friday morning, Seeking Alpha posts a calendar of the next week's expected biotech events to start a forward-looking conversation. Please be aware that dates and events can be subject to change. Please let us know in a comment or message if you...
IMDZ: 22.78 (+1.67), ARGS: 7.88 (+0.20), RXII: 0.50 (-0.01), CTSO: 6.24 (+0.31), ADK: 3.97 (-0.03), RGDX: 0.34 (+0.01), CLDN: 2.22 (+0.04)
NUO Therapeutics to Hold Fourth Quarter and Full Year 2014 Conference Call on Wednesday, April 1 at 8:00 a.m. Eastern Time
GlobeNewswire - Wed Mar 25, 7:45AM CDT
NUO Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, announced today that it will report financial results for the fourth quarter and full year 2014 on Tuesday, March 31, 2015, after the close of market.
Malignant Glioma Therapeutics Pipeline Review 2015 - 10 Companies & 18 Drug Profiles
M2 - Tue Mar 03, 5:44AM CST
Research and Markets (http://www.researchandmarkets.com/research/5rhrvv/malignant_glioma) has announced the addition of the "Malignant Glioma - Pipeline Review, H1 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Malignant Glioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Glioma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Advantagene, Inc. - Eli Lilly and Company - iDD biotech SAS - Lipopharma Therapeutics SL - Merck & Co., Inc. - Nuo Therapeutics, Inc. - Orbus Therapeutics, Inc. - Sanofi - Stemline Therapeutics, Inc. - ZIOPHARM Oncology, Inc. Drug Profiles - Ad-RTS-IL-12 - ALD-451 - Dendritic Cell Therapy for Malignant Gliomas - Dendritic Cell Therapy for Oncology - eflornithine hydrochloride - galunisertib - GliAtak - IDD-004 - LD-224 - marizomib - Minerval - Monoclonal Antibody Conjugated to Antagonize EGFR for Brain Tumor and Glioblastoma Multiforme - pembrolizumab - SL-701 - Small Molecule for Brain Cancer and Malignant Glioma - Vaccine to Target Survivin for Malignant Glioma - Vaccine to Target Wilm's Tumor 1 for Oncology - voxtalisib For more information visit http://www.researchandmarkets.com/research/5r...ant_glioma
ZIOP: 9.35 (+0.18), MRK: 60.01 (-0.22), LLY: 72.94 (+0.04), STML: 13.42 (-0.01)
Nuo Therapeutics Initiates Phase 4 Study of Aurix(TM) Under CMS Coverage With Evidence Development Program
GlobeNewswire - Thu Feb 19, 7:30AM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced the initiation of a new clinical study (Au Study) that is comprised of three randomized controlled protocols that examine the efficacy of Aurix(TM), a biodynamic hematogel, for use in diabetic foot ulcers, venous leg ulcers and pressure ulcers (bed sores).
Coronary Artery Disease Therapeutics Pipeline Market H1 2015 Research Report Available at RnRMarketResearch.com
PRWeb - Thu Feb 05, 7:31AM CST
The report "Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease). Coronary artery disease (Ischemic Heart Disease) is the most common type of heart disease. Coronary artery disease is the tightening or blockage of the coronary arteries. A severe adequate blockage may cause a heart attack. Coronary artery disease (Ischemic Heart Disease) is the foremost cause of death in US, UK and globally. Most ischaemic heart disease is caused by atherosclerosis. However there are a number of risk factors.
CRME: 9.03 (+0.34), GILD: 111.00 (+1.70), PSTI: 2.72 (+0.04), MRK: 60.01 (-0.22), AZN: 68.74 (-0.55), EGRX: 61.94 (+1.02), BMY: 68.00 (+0.36), RGDO: 1.21 (unch)
Nuo Therapeutics and Rohto Pharmaceutical Co. Sign Exclusive Licensing and Distribution Agreement for Aurix in Japan
GlobeNewswire - Thu Jan 08, 3:06PM CST
Nuo Therapeutics, Inc. (OTCQX:NUOT) a pioneer in biodynamic therapies, today announced that it has signed an exclusive licensing and distribution agreement for the Aurix System with Rohto Pharmaceutical Co., Ltd. ("Rohto"
, one of Japan's leading pharmaceutical, health and wellness companies. Under the terms of the agreement, Nuo will receive an upfront payment from Rohto in exchange for an exclusive license and the right to develop and commercialize Aurix in the Japanese market. The agreement also contemplates additional royalty payments based on the net sales of Aurix in Japan and an additional future cash payment in the event specific milestones are met. In turn, Nuo will pay a one-time fee to Millennia Holdings (Millennia) to terminate the September 2009 license and distribution agreement. Millennia has been instrumental in establishing the advanced wound care market in Japan, and will continue to work with Rohto to develop the market for Aurix. Further, Rohto has assumed all responsibility for securing the Marketing Authorization ("MA" from Japan's Ministry of Health, Labour and Welfare ("MHLW" , while Nuo will provide relevant product information, as well as clinical and other data to support Rohto's MA application. 15 Biotech Names For 2015
Jason Napodano, CFA - at Seeking Alpha - Mon Jan 05, 1:37PM CST
NBIX: 43.14 (+1.51), NVIV: 12.09 (-0.97), LPCN: 7.60 (-0.06), EPRS: 5.94 (+0.33), DEPO: 20.22 (-0.32), ASPX: 100.96 (unch), BCLI: 3.59 (-0.07), CUR: 1.71 (+0.01)
Critical Limb Ischemia - Pipeline Review, H2 2014
M2 - Wed Dec 10, 4:50AM CST
Research and Markets (http://www.researchandmarkets.com/research/m55nsq/critical_limb) has announced the addition of the "Critical Limb Ischemia - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Critical Limb Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Critical Limb Ischemia and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Critical Limb Ischemia - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Critical Limb Ischemia pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Aastrom Biosciences - AnGes MG - Apceth GmbH & Co - Athersys - Hemostemix - Human Stem Cells Institute - Juventas Therapeutics - Kasiak Research - Multi Gene Vascular Systems - NeoStem - Nuo Therapeutics - Pharmicell - Pluristem Therapeutics - ReNeuron Group - Stempeutics Research Private - TikoMed - ViroMed For more information visit http://www.researchandmarkets.com/research/m5...tical_limb
PSTI: 2.72 (+0.04)
Nuo Therapeutics Wins 2014 MarCom Platinum Award
GlobeNewswire - Tue Dec 02, 7:30AM CST
Nuo Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced that it, along with its marketing partner BLDG Health, was presented with the 2014 Platinum MarCom Award by the Association of Marketing and Communication Professionals (AMCP) for its sales education modules designed to support the recently launched Aurix System(TM). In addition, Nuo and BLDG Health were awarded with an Honorable Mention for the Aurix System(TM) microsite in the 2014 competition.
Nuo Therapeutics to Sponsor Pre-Event for 35th National Veterans Wheelchair Games
GlobeNewswire - Mon Nov 17, 7:42AM CST
Nuo Therapeutics (OTCQX:NUOT), a pioneer in biodynamic therapies, today announced that it is sponsoring the 35 National Veterans Wheelchair Games Business & Community Leaders' Breakfast, co-presented by the Paralyzed Veterans of America (PVA) and the U.S. Department of Veterans Affairs (VA), taking place November 18, 2014 at Southern Methodist University in Dallas, Texas. This sponsorship marks the first in a series of initiatives reinforcing the Company's commitment to the PVA and the members it serves.
Nuo Therapeutics' (NUOT) CEO Marty Rosendale on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Fri Nov 14, 1:34PM CST
